Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...89101112131415161718...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2451;    
    Earlier treatment lines favored better PFS, with patients treated with TKI as a fourth line reaching a median of 1.28 months compared to 5.97 months as a second and 6.33 months as a third line (p<0.001). Conclusions : These findings suggest that TKIs are efficacious as second or post-line treatments and represent a viable treatment option for Hispanic patients with advanced TETs.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  STELLAR: A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Jul 18, 2024   
    P=N/A,  N=335, Completed, 
    The promising machine learning radiomics model was developed and validated to predict the efficacy of LPI therapy for patients with HCC and perform risk stratification, with comparable performance to clinical-radiomics model. Active, not recruiting --> Completed | N=1000 --> 335 | Trial completion date: Mar 2031 --> Dec 2023 | Trial primary completion date: Mar 2031 --> Dec 2023
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial primary completion date, Tumor mutational burden, IO biomarker, Metastases:  JS001-027-III-HCC: Phase III Study of Toripalimab?JS001? Combined With Lenvatinib for Advanced HCC (clinicaltrials.gov) -  Jul 17, 2024   
    P3,  N=530, Active, not recruiting, 
    Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026 Trial primary completion date: May 2024 --> May 2025
  • ||||||||||  Retrospective data, Journal, Metastases:  Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience. (Pubmed Central) -  Jul 16, 2024   
    Trial primary completion date: May 2024 --> May 2025 While neoadjuvant therapy achieved tumoral responses, surgical resection was feasible in 50% of DTC, 33% of ATC, and 16% of MTC patients, with R0/R1 resection in 26% of the cohort, underscoring the need for patient selection and further research in this area.
  • ||||||||||  Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Review, Journal, Metastases:  An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. (Pubmed Central) -  Jul 11, 2024   
    Management of thyroid carcinomas has evolved such that targeted therapies have become therapeutic options for patients with BRAF, RET, NTRK, ALK, and ROS1 alterations and even have reported efficacy in anaplastic thyroid carcinomas. In this article, we review the advances made over the years in the treatment of metastatic thyroid carcinoma and focus on the systemic therapies that have recently transformed the treatment landscape of advanced disease.
  • ||||||||||  Zarnestra (tipifarnib) / Kura Oncology, Bosulif (bosutinib) / Pfizer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents. (Pubmed Central) -  Jul 10, 2024   
    The current review offers recent advances in quinoline derivatives as anticancer agents for green synthesis using microwave, ultrasound, and one-pot synthesis. We believe that our findings will provide useful insight and inspire more green research on this framework to produce powerful and selective quinoline derivatives.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, PD(L)-1 Biomarker:  Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab. (Pubmed Central) -  Jul 9, 2024   
    Multivariate analysis results indicated that both early AFP response and AFP response independently predicted OS [hazard ratio (HR) 2.963, 95% confidence interval (CI) 1.333-6.585, p=0.008, and HR 6.182, 95% CI 1.780-21.466, p=0.004] and PFS (HR 2.186, 95% CI 1.107-4.318, p=0.024, and HR 3.078, 95% CI 1.407-6.730, p=0.005), serving as significant prognostic values. Early AFP response and AFP response serve as predictive biomarkers for the effectiveness of HAIC combined with lenvatinib and camrelizumab in patients with u-HCC.
  • ||||||||||  Review, Journal, HEOR, Checkpoint inhibition, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review. (Pubmed Central) -  Jul 5, 2024   
    The current evidence showed that ICIs, including atezolizumab plus bevacizumab, sintilimab plus bevacizumab/bevacizumab biosimilar, nivolumab, camrelizumab plus rivoceranib, pembrolizumab plus lenvatinib, tislelizumab, durvalumab, and cabozantinib plus atezolizumab, are probably not cost-effective in comparison with tyrosine kinase inhibitors or other ICIs...Our review demonstrated that ICIs were not a cost-effective intervention in advanced HCC. Although ICIs can significantly enhance the survival of patients with advanced HCC, decision-makers should consider the findings of economic evaluations and affordability before adoption of new therapies.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Enrollment closed, Trial initiation date, Metastases:  Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma (clinicaltrials.gov) -  Jul 2, 2024   
    P2,  N=50, Active, not recruiting, 
    Therefore, careful monitoring is required for potentially high-risk patients undergoing ICI combination therapy. Recruiting --> Active, not recruiting | Initiation date: Nov 2023 --> Jul 2023